Title:The Role of Tumor Suppressor DLC-1: Far From Clear
Volume: 17
Issue: 7
Author(s): Xu Liu, Yao-Jie Pan, Jun-Nian Zheng*Dong-Sheng Pei*
Affiliation:
- Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu,China
- Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu,China
Keywords:
DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.
Abstract: Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and
was often found to be deleted in hepatocellular carcinoma (HCC).
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using
a focused review question and inclusion/exclusion criteria.
Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as
well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1
as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found
to play a pivotal role in regulating DLC-1.
Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream
signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms
linked to DLC-1 remain undefined.
